Use of siltuximab in patients with COVID-19 pneumonia requiring ventilatory support

COVID-19 is caused by the Severe Acute Respiratory Syndrome Coronavirus-2 (SAR-CoV-2), resulting in symptoms, such as fever, cough, and shortness of breath. The SARS-CoV-2 virus has also been suggested to initiate a cytokine storm in patients with COVID-19 evidenced by elevated cytokines, such as interleukin-6 (IL-6) and C-reactive protein (CRP). We report preliminary data from 21 patients with COVID-19 who developed pneumonia/acute respiratory distress syndrome (ARDS) and participated in a compassionate-use program at Papa Giovanni XXIII hospital in Bergamo, Italy. All 21 patients received intravenous siltuximab, a chimeric mAb that binds to and blocks the effect of IL-6, at a dose ranging between 700 to 1,200 mg (median 900 mg). The median age of patients treated was 64 years, and all patients were followed for a median of eight days. Serum CRP levels reduced in all 16 patients with available data following treatment. An improvement in the clinical condition was observed in 33% (7/21) of patients, 43% (9/21) of patients stabilized as evidenced by no clinically relevant change in their condition, and 24% (5/21) experienced a worsening in their condition. Of those patients who experienced a worsening in their condition, one patient died, and one patient experienced a cerebrovascular event. This analysis is presented to inform the medical community of the potential role of siltuximab in treating patients with ARDS secondary to SARS-CoV-2 infection, and a cohort study with patients treated with standard therapy in our hospital is ongoing, and will report the 30-day mortality rates upon completion.

data following treatment. An improvement in the clinical condition was observed in 33% (7/21) of patients, 43% (9/21) of patients stabilized as evidenced by no clinically relevant change in their condition, and 24% (5/21) experienced a worsening in their condition. Of those patients who experienced a worsening in their condition, one patient died, and one patient experienced a cerebrovascular event.
This analysis is presented to inform the medical community of the potential role of siltuximab in treating patients with ARDS secondary to SARS-CoV-2 infection, and a cohort study with patients treated with standard therapy in our hospital is ongoing, and will report the 30-day mortality rates upon completion.
Introduction COVID-19 is caused by the Severe Acute Respiratory Syndrome Coronavirus-2 (SAR-CoV-2), resulting in symptoms, such as fever, cough, and shortness of breath.
SARS-CoV and the Middle East respiratory syndrome CoV (MERS-CoV) are highly pathogenic coronaviruses that infect the lower respiratory tract causing severe pneumonia that results in rapid viral replication, massive inflammatory cell infiltration and elevated pro-inflammatory cytokine levels including Interleukin-6 (IL-6) and Creactive protein (CRP) that lead to severe respiratory failure, which can be described as acute respiratory distress syndrome (ARDS) (Channappanavar R and Perlman S. 2017). The SARS-CoV-2 virus has also been suggested to initiate a cytokine storm in patients with COVID-19 (Mehta P et al. 2020). IL-6 blockade has been identified as a potential strategy to mitigate the complications associated with COVID-19 infection.
Tocilizumab, an IL-6R targeted monoclonal antibody (mAb), received rapid approval in China for treatment of patients with severe COVID-19 and extensive lung damage (National Health Commission of China, 2020;Xu X et al. 2020). We report preliminary data from 21 patients with COVID-19 who developed serious respiratory complications and were treated with siltuximab, a chimeric mAb that binds to and blocks the effect of IL-6 (NCT04322188). Siltuximab is approved by the European Medicines Agency and the Food and Drug Administration of the USA for treatment of adults with multicentric Castleman's disease who are human immunodeficiency virus and human herpes virus-8 negative (EUSA 2019).
. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
(which was not peer-reviewed) The copyright holder for this preprint . https://doi.org/10. 1101 Methods This investigator-led study retrospectively analysed data collected on patients with pulmonary infection by SARS-CoV-2 (confirmed by clinical and radiological assessment) and ARDS (in accordance with the Berlin 2012 criteria) (Definition Task Force ARDS, 2012) who were admitted to the Papa Giovanni XXIII Hospital in Bergamo, Italy. Patients were treated according to the hospital standard of care, and received treatment with siltuximab administered intravenously at a dose of 11 mg/kg/day over 1 hour. A second dose could be administered at the physician's discretion, as part of a compassionate-use program approved by the Hospital Ethics Board. Data analysis was completed on 27 March 2020, when all patients had at least 7 days of follow-up after siltuximab administration.
All patients, or their legal representative, provided consent to participate in the study.

Baseline patient and disease characteristics
Between 11 March 2020 and 24 March 2020, 21 patients with confirmed COVID-19 were admitted to the hospital. The median age of patients was 64 years (range 48-75 years), and more men than women were treated: 85.7% of (18/21) patients were male.
At baseline, serum CRP results were elevated in all patients (median 23.4 mg/dL; range 9.5 to 43.1 mg/dL). The IL-6 levels were available for 19/21 patients and were outside of the normal range: median 139.5 pg/mL; range 113, 239 pg/mL ( Table 2).
The PaO2/FiO2 (partial pressure of arterial oxygen over the fraction of inspired oxygen) ratio was available for 20/21 patients, and the baseline median value was 127 (range 69.0 to 291.0). All the 21 patients in the study, required ventilation by either continuous positive airway pressure (CPAP) or non-invasive ventilation (NIV).

Siltuximab administration
All 21 patients received siltuximab at a median dose of 900 mg, ranging from 700 to 1,200 mg (Table 3). Five patients received a second dose of siltuximab; for three of these five patients the infusions were two days apart, and for two of these patients the infusions were three days apart. Patients were treated with siltuximab within two days after initiating ventilation with either CPAP or NIV. The median follow-up for all patients was eight days.
. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not peer-reviewed)
The copyright holder for this preprint .

Patient response to treatment with siltuximab
Following treatment with siltuximab, serum CRP levels reduced to within the normal range by Day 5 and remained stable in all 16 patients with available data throughout the follow-up period (Figure 1).
In addition, 33% (7/21) of patients experienced an improvement in their condition with a reduced need for ventilation (i.e. patients were removed from CPAP and NIV), 43% (9/21) of patients experienced a stabilizing of their condition, and 24% (5/21) of patients experienced a worsening of their condition and required intubation (Table 4).
One patient developed a cerebrovascular event.
. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

Discussion
This compassionate-use program was initiated to understand the feasibility of suppressing CRP production with siltuximab and improving the outcomes in patients with COVID-19 requiring CPAP or NIV for pneumonia/ARDS treatment. Initial evidence from China where the first cases of COVID-19 emerged, indicate that excessive production inflammatory markers, such as IL-6 and CRP, correlate with severity of disease (Chen X et al. 2020;Conti P et al. 2020;Diao B et al. 2020;Gong J et al. 2020;Liu et al. 2020;Yang et al. 2020), and many more studies report a significant increase in IL-6 or CRP levels in patients with severe or critical COVID-19 compared with those patients with mild disease (Cai et al. 2020;Chen J et al. 2020;Feng C et al. 2020;Huang Y et al. 2020;Liu J et al. 2020;Qin C et al. 2020;Ruan Q et al. 2020;Shi Y et al. 2020;Wang Y et al 2020;Wang Z et al. 2020;Wu C et al.2020;Xu W et al. 2020;Xu X et al. 2020;Zeng Q et al. 2020;Zhao Z et al. 2020;Zhang B et al. 2020;Zhou F et al. 2020;Zhou Y et al. 2020).
Similarly, data from our retrospective analysis also show that baseline IL-6 levels and serum CRP levels were elevated beyond the normal range in all of the patients with available data, indicating the presence of inflammation, and suggesting that these . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not peer-reviewed)
The copyright holder for this preprint . https: //doi.org/10.1101//doi.org/10. /2020 The limitations of this report include that the compassionate-use program was set-up in a short period of time, to determine the effectiveness of siltuximab to reduce serum CRP levels, and understand whether IL-6 and CRP levels can be controlled to improve the outcomes for patients with pneumonia/ARDS associated with COVID-19. In addition, the report includes a short follow-up period with a limited number of patients.
This analysis is presented to inform the medical community of the potential role of siltuximab in treating patients with SARS-CoV-2 infection who develop pneumonia/ARDS requiring CPAP/NIV. A cohort study matching patients treated with siltuximab to those treated with standard therapy at our hospital is ongoing and will report full clinical outcome upon completion. With extended follow-up, we anticipate that the natural history of the disease shall be better described.
. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not peer-reviewed)
The copyright holder for this preprint . https://doi.org/10.1101/2020.04.01.20048561 doi: medRxiv preprint  (100) Mechanical ventilation 0 . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not peer-reviewed)
The copyright holder for this preprint . https: //doi.org/10.1101//doi.org/10. /2020   Patients not receiving second dose 16 (76.19) *One patient who was moved to the intensive care unit and subsequently died **For 3 patients, the two infusions were 2 days apart, and for 2 patients, they were 3 days apart . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not peer-reviewed)
The copyright holder for this preprint . https://doi.org/10.1101/2020.04.01.20048561 doi: medRxiv preprint Worsening of condition (intubation or death) 5 (24) . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
(which was not peer-reviewed) The copyright holder for this preprint . https://doi.org/10.1101/2020.04.01.20048561 doi: medRxiv preprint Figure 1: Individual patient serum CRP levels following siltuximab treatment for 7 days following treatment with siltuximab (silutixmab administration at Day 1 (N=21). Each line represents an individual patient. Days following siltuximab administration Patient serum CRP levels, mg/dL . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.